Ligand Pharm (LGND)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2025 | 06-2025 | 03-2025 | 12-2024 | 09-2024 | |
| Sales | 115,461 | 47,627 | 45,333 | 42,812 | 51,812 |
| Cost of Goods | 3,801 | 2,907 | 4,849 | 2,837 | 2,449 |
| Gross Profit | 111,660 | 44,720 | 40,484 | 39,975 | 49,363 |
| Operating Expenses | 57,530 | 37,183 | 77,549 | 50,449 | 46,669 |
| Operating Income | 54,931 | 8,444 | -36,216 | -9,637 | 3,143 |
| Interest Expense | 910 | 1,153 | 867 | 887 | 741 |
| Other Income | 87,116 | 3,932 | -13,097 | -28,676 | -8,741 |
| Pre-tax Income | 141,137 | 11,223 | -50,180 | -39,200 | -6,339 |
| Income Tax | 23,864 | 6,376 | -7,729 | -8,112 | 833 |
| Net Income Continuous | 117,273 | 4,847 | -42,451 | -31,088 | -7,172 |
| Net Income | $117,273 | $4,847 | $-42,451 | $-31,088 | $-7,172 |
| EPS Basic Total Ops | 5.99 | 0.25 | -2.21 | -1.81 | -0.39 |
| EPS Basic Continuous Ops | 5.99 | 0.25 | -2.21 | -1.81 | -0.39 |
| EPS Diluted Total Ops | 5.68 | 0.24 | -2.21 | -1.70 | -0.39 |
| EPS Diluted Continuous Ops | 5.68 | 0.24 | -2.21 | -1.70 | -0.39 |
| EPS Diluted Before Non-Recurring Items | 5.68 | 0.24 | -2.21 | -1.64 | -0.39 |
| EBITDA(a) | $62,309 | $16,325 | $-28,149 | $-1,444 | $12,133 |